EUCTR2011-000240-16-SE进行中（未招募）不适用
A MULTICENTER PHASE II STUDY EVALUATING EFFICACY AND SAFETY OF 177Lu-DOTA-TATE BASED ON KIDNEY-DOSIMETRY IN PATIENTS WITH DISSEMINATED NEUROENDOCRINE TUMORS - ILUMINET
Skånes Onkologiska Klinik, Skåne University Hospital, Lund0 个研究点目标入组 100 人开始时间: 2011年4月7日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 70
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- 未提供
研究者
相似试验
招募中
不适用
A Multi-center Phase II Study evaluating efficacy and safety of Dasatinib in Patients with newly diagnosed Philadelphia(Ph) chromosome positive Chronic Myeloid Leukemia in chronic phase.Chronic Myeloid LeukemiaJPRN-UMIN000005843Epidemiological and Clinical Research Information Network (ECRIN)30
进行中（未招募）
1 期
A study in HER-2 negative metastatic breast cancer patients receiving ModraDoc006/r, an oral chemotherapy treatment regime of docetaxelrecurrent/ metastatic HER-2 negative breast cancer, suitable for treatment with a taxaneMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003249-41-DKModra Pharmaceuticals B.V.24
进行中（未招募）
1 期
A study in HER-2 negative metastatic breast cancer patients receiving ModraDoc006/r, an oral chemotherapy treatment regime of docetaxelrecurrent/ metastatic HER-2 negative breast cancer, suitable for treatment with a taxaneEUCTR2018-003249-41-BEModra Pharmaceuticals B.V.24
进行中（未招募）
1 期
A study in HER-2 negative metastatic breast cancer patients receiving ModraDoc006/r, an oral chemotherapy treatment regime of docetaxelrecurrent/ metastatic HER-2 negative breast cancer, suitable for treatment with a taxaneMedDRA version: 20.0 Level: PT Classification code 10006187 Term: Breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003249-41-ESModra Pharmaceuticals B.V.24
进行中（未招募）
不适用
A multicenter phase II study to determine the efficacy of capecitabine as first line monochemotherapy in patients with HER2 negative, medium-risk, metastatic breast cancer - Monica StudyEUCTR2005-000074-51-DEGBG Forschungs GmbH